DCTH

Delcath Systems, Inc. (NASDAQ:DCTH) is a specialized interventional oncology company founded in 1988 and headquartered in New York, New York. The company focuses on developing and commercializing innovative treatments for primary and metastatic liver cancers. After decades of development, Delcath achieved a major milestone in 2024 with the U.S. commercial launch of its flagship product HEPZATO KIT, following FDA approval for treating metastatic uveal melanoma. The company also markets its technology in Europe under the CHEMOSAT brand name and is actively expanding its clinical programs to address additional cancer indications.